AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2022
Jan 5, 2022
33483_dirs_2022-01-05_d554d2a8-85ff-4d86-8d02-6b76028140c1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2022-01-03
Reporting Person: COX CARRIE SMITH (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-03 | Stock Option (Right to Buy) | $3.31 | A | 60000 | Acquired | 2032-01-02 | Common Stock (60000.0) | Direct |
Footnotes
F1: The shares of Common Stock underlying this award will vest in full on January 3, 2023.
More from Cartesian Therapeutics, Inc.
Capital/Financing Update
2026
May 26
Share Issue/Capital Change
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Board/Management Information
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Investor Presentation
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8